SU1424732A3 - Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей - Google Patents
Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей Download PDFInfo
- Publication number
- SU1424732A3 SU1424732A3 SU813358051A SU3358051A SU1424732A3 SU 1424732 A3 SU1424732 A3 SU 1424732A3 SU 813358051 A SU813358051 A SU 813358051A SU 3358051 A SU3358051 A SU 3358051A SU 1424732 A3 SU1424732 A3 SU 1424732A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- dimethoxy
- diamino
- compounds
- mol
- mixture
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- -1 2,4-diamino-5-(substituted)pyrimidines Chemical class 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- ZEZQUIOIQGCIGP-UHFFFAOYSA-N 7,8-dimethoxy-2h-chromene-5-carbaldehyde Chemical compound C1=CCOC2=C(OC)C(OC)=CC(C=O)=C21 ZEZQUIOIQGCIGP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960001082 trimethoprim Drugs 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KWYYQBBAPJWTKT-UHFFFAOYSA-N 5-[(8-methoxyquinolin-5-yl)methyl]pyrimidine-2,4-diamine;dihydrochloride Chemical compound Cl.Cl.C12=CC=CN=C2C(OC)=CC=C1CC1=CN=C(N)N=C1N KWYYQBBAPJWTKT-UHFFFAOYSA-N 0.000 description 2
- ACOHRGDSJSALMU-UHFFFAOYSA-N 8-methoxyquinoline-5-carbaldehyde Chemical compound C1=CN=C2C(OC)=CC=C(C=O)C2=C1 ACOHRGDSJSALMU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RWLQYLNOKVTREC-UHFFFAOYSA-N CC1=CC(=C2C=CC=NC2=C1N(C)C)C=O Chemical compound CC1=CC(=C2C=CC=NC2=C1N(C)C)C=O RWLQYLNOKVTREC-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- RQPYRZVLFKRPTE-UHFFFAOYSA-N 2-[(7,8-dimethoxy-2h-chromen-5-yl)methyl]-3-morpholin-4-ylprop-2-enenitrile Chemical compound C=12C=CCOC2=C(OC)C(OC)=CC=1CC(C#N)=CN1CCOCC1 RQPYRZVLFKRPTE-UHFFFAOYSA-N 0.000 description 1
- OOLOAWZLPBDRJQ-UHFFFAOYSA-N 2-benzylpyrimidine Chemical compound N=1C=CC=NC=1CC1=CC=CC=C1 OOLOAWZLPBDRJQ-UHFFFAOYSA-N 0.000 description 1
- UUVGOTJBHRZFFI-UHFFFAOYSA-N 3-(7,8-dimethoxy-2h-chromen-5-yl)-2-(methoxymethyl)prop-2-enenitrile Chemical compound O1CC=CC2=C1C(OC)=C(OC)C=C2C=C(COC)C#N UUVGOTJBHRZFFI-UHFFFAOYSA-N 0.000 description 1
- MUSJJKWJSXQFHL-UHFFFAOYSA-N 3-anilino-2-[(8-methoxyquinolin-5-yl)methyl]prop-2-enenitrile Chemical compound C12=CC=CN=C2C(OC)=CC=C1CC(C#N)=CNC1=CC=CC=C1 MUSJJKWJSXQFHL-UHFFFAOYSA-N 0.000 description 1
- OOWFYDWAMOKVSF-UHFFFAOYSA-N 3-methoxypropanenitrile Chemical compound COCCC#N OOWFYDWAMOKVSF-UHFFFAOYSA-N 0.000 description 1
- WXVKGHVDWWXBJX-UHFFFAOYSA-N 3-morpholin-4-ylpropanenitrile Chemical compound N#CCCN1CCOCC1 WXVKGHVDWWXBJX-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- LIADJWREMDHKHQ-UHFFFAOYSA-N 8-hydroxyquinoline-5-carbaldehyde Chemical compound C1=CN=C2C(O)=CC=C(C=O)C2=C1 LIADJWREMDHKHQ-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OGFZEDMIYDGMQJ-UHFFFAOYSA-N [Na].COC(C)=O Chemical compound [Na].COC(C)=O OGFZEDMIYDGMQJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- TUCHVHWHPRXOOO-UHFFFAOYSA-N guanidine;methanol Chemical compound OC.NC(N)=N TUCHVHWHPRXOOO-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QWTZLOAESKJVHT-UHFFFAOYSA-N methyl 3,4-dimethoxy-5-prop-2-ynoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C(OCC#C)=C1 QWTZLOAESKJVHT-UHFFFAOYSA-N 0.000 description 1
- LCIFXEQPXQVBGL-UHFFFAOYSA-N methyl 3-hydroxy-4,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(O)=C(OC)C(OC)=C1 LCIFXEQPXQVBGL-UHFFFAOYSA-N 0.000 description 1
- IEPZMWMSXDUQCA-UHFFFAOYSA-N methyl 7,8-dimethoxy-2h-chromene-5-carboxylate Chemical compound O1CC=CC2=C1C(OC)=C(OC)C=C2C(=O)OC IEPZMWMSXDUQCA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8036135 | 1980-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1424732A3 true SU1424732A3 (ru) | 1988-09-15 |
Family
ID=10517217
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813358051A SU1424732A3 (ru) | 1980-11-11 | 1981-11-10 | Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей |
| SU833543245A SU1318148A3 (ru) | 1980-11-11 | 1983-01-27 | Способ получени 2,4-диамино-5-(замещенных)пиримидинов |
| SU833547444A SU1306473A3 (ru) | 1980-11-11 | 1983-01-31 | Способ получени 2,4-диамино-5-(замещенных) пиримидинов |
| SU874028793A SU1535379A3 (ru) | 1980-11-11 | 1987-01-14 | Способ получени 5-замещенных 2,4-диаминопиримидинов или их кислотно-аддитивных солей |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU833543245A SU1318148A3 (ru) | 1980-11-11 | 1983-01-27 | Способ получени 2,4-диамино-5-(замещенных)пиримидинов |
| SU833547444A SU1306473A3 (ru) | 1980-11-11 | 1983-01-31 | Способ получени 2,4-диамино-5-(замещенных) пиримидинов |
| SU874028793A SU1535379A3 (ru) | 1980-11-11 | 1987-01-14 | Способ получени 5-замещенных 2,4-диаминопиримидинов или их кислотно-аддитивных солей |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US4438267A (OSRAM) |
| EP (1) | EP0051879B1 (OSRAM) |
| JP (1) | JPS57114581A (OSRAM) |
| KR (1) | KR880001736B1 (OSRAM) |
| AR (1) | AR245447A1 (OSRAM) |
| AU (1) | AU549449B2 (OSRAM) |
| CA (1) | CA1186310A (OSRAM) |
| CS (1) | CS273153B2 (OSRAM) |
| CY (1) | CY1419A (OSRAM) |
| DD (1) | DD201896A5 (OSRAM) |
| DE (1) | DE3173752D1 (OSRAM) |
| DK (1) | DK172884B1 (OSRAM) |
| EG (1) | EG16107A (OSRAM) |
| ES (5) | ES8307759A1 (OSRAM) |
| FI (1) | FI76333C (OSRAM) |
| GB (1) | GB2087881B (OSRAM) |
| GR (1) | GR81317B (OSRAM) |
| HK (1) | HK23388A (OSRAM) |
| HU (1) | HU188762B (OSRAM) |
| IE (1) | IE52128B1 (OSRAM) |
| IL (1) | IL64256A (OSRAM) |
| IT (1) | IT1210589B (OSRAM) |
| MC (1) | MC1418A1 (OSRAM) |
| MY (1) | MY8600678A (OSRAM) |
| NO (2) | NO160137C (OSRAM) |
| NZ (1) | NZ198932A (OSRAM) |
| PH (2) | PH25053A (OSRAM) |
| PL (4) | PL139427B1 (OSRAM) |
| PT (1) | PT73960B (OSRAM) |
| RU (1) | RU1819264C (OSRAM) |
| SG (1) | SG62686G (OSRAM) |
| SU (4) | SU1424732A3 (OSRAM) |
| YU (5) | YU42444B (OSRAM) |
| ZA (1) | ZA817780B (OSRAM) |
| ZM (1) | ZM9481A1 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2141322C1 (ru) * | 1997-08-12 | 1999-11-20 | Голощапов Николай Михайлович | Иммуномодулятор с антимикобактериальной активностью "изофон", способ его получения и применения |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438267A (en) * | 1980-11-11 | 1984-03-20 | Daluge Susan M | Monoheteroring compounds and their use |
| DK190983A (da) * | 1982-05-01 | 1983-11-02 | Wellcome Found | 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor |
| US4590271A (en) * | 1982-05-01 | 1986-05-20 | Burroughs Wellcome Co. | 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials |
| ZA833067B (en) * | 1982-05-01 | 1984-12-24 | Wellcome Found | Antibacterial compounds |
| US4587341A (en) * | 1982-05-07 | 1986-05-06 | Burroughs Wellcome Co. | 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials |
| CA1244028A (en) * | 1983-04-14 | 1988-11-01 | Hans Maag | Pyrimidine derivatives |
| GB8603964D0 (en) * | 1986-02-18 | 1986-03-26 | Cooper Animal Health Ltd | Compositions |
| GB8603962D0 (en) * | 1986-02-18 | 1986-03-26 | Wellcome Found | Chemical compositions |
| LU86703A1 (fr) * | 1986-12-08 | 1988-07-14 | Oreal | Composition cosmetique photostable contenant un filtre uv-a et un filtre uv-b,son utilisation pour la protection de la peau contre les rayons uv et procede de stabilisation du filtre uv-a par le filtre uv-b |
| FI895821A7 (fi) * | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB8903978D0 (en) * | 1989-02-22 | 1989-04-05 | Coopers Animal Health | Chemical compositions |
| GB9000241D0 (en) * | 1990-01-05 | 1990-03-07 | Coopers Animal Health | Pharmaceutical use |
| RU95113597A (ru) * | 1992-12-02 | 1997-06-10 | ФМК Корпорейшн (US) | Инсектицидная композиция, способы борьбы с насекомыми |
| NO940245D0 (no) * | 1993-01-28 | 1994-01-24 | Takeda Chemical Industries Ltd | Quinolin eller quinazolinderivater, deres fremstilling og anvendelse |
| US5707996A (en) * | 1995-11-06 | 1998-01-13 | Macleod Pharmaceuticals, Inc. | Pharmaceutical solution and methods for preparation thereof |
| JP3309340B2 (ja) * | 1995-12-04 | 2002-07-29 | アルピダ・アーゲー | ジアミノピリミジン、それらを含む医薬組成物及びそれらの抗菌剤としての用途 |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| WO2002010156A1 (en) * | 2000-07-29 | 2002-02-07 | Arpida Ag | Benzofuran derivatives and their use as antibacterial agents |
| ES2266553T3 (es) * | 2001-06-29 | 2007-03-01 | Ab Science | Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias. |
| US7727731B2 (en) * | 2001-06-29 | 2010-06-01 | Ab Science | Potent, selective and non toxic c-kit inhibitors |
| US7700610B2 (en) * | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
| ES2274075T3 (es) | 2001-06-29 | 2007-05-16 | Ab Science | Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii). |
| CA2460845A1 (en) * | 2001-09-20 | 2003-03-27 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| US20040242612A1 (en) * | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of tyrosine kinase inhibitors for promoting hair growth |
| JP2005507916A (ja) * | 2001-09-20 | 2005-03-24 | アブ サイエンス | 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法 |
| ATE469146T1 (de) * | 2003-07-11 | 2010-06-15 | Arpida Ag | Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen |
| CN102079727A (zh) * | 2005-02-18 | 2011-06-01 | 阿皮德公开股份有限公司 | 用于制备2h-色烯的方法 |
| JP4850912B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン |
| US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| US20120122819A1 (en) * | 2009-06-12 | 2012-05-17 | Socpra - Sciences Et Genie S.E.C. | Guanine riboswitch binding compounds and their use as antibiotics |
| CN102649786B (zh) * | 2011-02-28 | 2014-08-27 | 郑州福源动物药业有限公司 | 一种2，4-二氨基-5-(8-二甲氨基-7-甲基-5-喹啉基甲基)-2，4-(1h，3h)嘧啶的制备方法 |
| CN103755684B (zh) * | 2014-02-10 | 2015-09-09 | 青岛蔚蓝生物股份有限公司 | 一种巴喹普林的制备方法 |
| EP3981765A4 (en) * | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE |
| CN110818694B (zh) * | 2019-11-18 | 2023-04-21 | 上海医药工业研究院有限公司 | 艾拉普林中间体及其应用 |
| EP4320104A4 (en) * | 2021-04-09 | 2025-06-04 | The Trustees of The University of Pennsylvania | CONTROL OF PROTEIN EXPRESSION WITH TMP-PROTAC COMPOUNDS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3049544A (en) * | 1962-08-14 | Method for the preparation of | ||
| DE1303727B (de) | 1959-09-03 | 1976-02-05 | Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London | Alpha-Arylidensubstituierte Propioni-Irile |
| US3956327A (en) * | 1969-03-06 | 1976-05-11 | Burroughs Wellcome Co. | Method of preparing 2,4-diamino-5-benzyl pyrimidines |
| BE792096A (fr) * | 1971-12-01 | 1973-05-30 | Hoffmann La Roche | Nouvelles benzylpyrimidines |
| GB1468374A (en) | 1974-03-06 | 1977-03-23 | Wellcome Found | Process for preparing a pyrimidine derivative |
| US4039543A (en) | 1974-12-24 | 1977-08-02 | Hoffmann-La Roche Inc. | Benzylpyrimidines |
| GB1582245A (en) * | 1976-06-09 | 1981-01-07 | Wellcome Found | Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives |
| DE2730467A1 (de) * | 1977-07-06 | 1979-01-18 | Basf Ag | Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4258045A (en) * | 1979-11-30 | 1981-03-24 | Merck & Co., Inc. | Inhibitor of dihydrofolate reductase |
| US4438267A (en) * | 1980-11-11 | 1984-03-20 | Daluge Susan M | Monoheteroring compounds and their use |
-
1981
- 1981-11-09 US US06/319,644 patent/US4438267A/en not_active Expired - Lifetime
- 1981-11-10 CS CS825781A patent/CS273153B2/cs unknown
- 1981-11-10 EG EG653/81A patent/EG16107A/xx active
- 1981-11-10 ES ES506969A patent/ES8307759A1/es not_active Expired
- 1981-11-10 KR KR1019810004348A patent/KR880001736B1/ko not_active Expired
- 1981-11-10 DK DK198104966A patent/DK172884B1/da active Protection Beyond IP Right Term
- 1981-11-10 PL PL1981239279A patent/PL139427B1/pl unknown
- 1981-11-10 PL PL1981233754A patent/PL139523B1/pl unknown
- 1981-11-10 GR GR66482A patent/GR81317B/el unknown
- 1981-11-10 ZA ZA817780A patent/ZA817780B/xx unknown
- 1981-11-10 PL PL1981239280A patent/PL139828B1/pl unknown
- 1981-11-10 YU YU2663/81A patent/YU42444B/xx unknown
- 1981-11-10 IL IL64256A patent/IL64256A/xx not_active IP Right Cessation
- 1981-11-10 MC MC811560A patent/MC1418A1/fr unknown
- 1981-11-10 JP JP56180271A patent/JPS57114581A/ja active Granted
- 1981-11-10 HU HU813359A patent/HU188762B/hu unknown
- 1981-11-10 CA CA000389807A patent/CA1186310A/en not_active Expired
- 1981-11-10 IE IE2631/81A patent/IE52128B1/en not_active IP Right Cessation
- 1981-11-10 PT PT73960A patent/PT73960B/pt unknown
- 1981-11-10 AU AU77334/81A patent/AU549449B2/en not_active Expired
- 1981-11-10 PL PL1981239278A patent/PL139827B1/pl unknown
- 1981-11-10 SU SU813358051A patent/SU1424732A3/ru active
- 1981-11-10 GB GB8133833A patent/GB2087881B/en not_active Expired
- 1981-11-10 IT IT8149676A patent/IT1210589B/it active
- 1981-11-10 NZ NZ198932A patent/NZ198932A/en unknown
- 1981-11-10 NO NO813804A patent/NO160137C/no not_active IP Right Cessation
- 1981-11-10 FI FI813546A patent/FI76333C/fi not_active IP Right Cessation
- 1981-11-10 DD DD81234745A patent/DD201896A5/de not_active IP Right Cessation
- 1981-11-11 CY CY141981A patent/CY1419A/xx unknown
- 1981-11-11 DE DE8181109631T patent/DE3173752D1/de not_active Expired
- 1981-11-11 ZM ZM94/81A patent/ZM9481A1/xx unknown
- 1981-11-11 EP EP81109631A patent/EP0051879B1/en not_active Expired
-
1983
- 1983-01-27 SU SU833543245A patent/SU1318148A3/ru active
- 1983-01-31 SU SU833547444A patent/SU1306473A3/ru active
- 1983-04-02 ES ES521202A patent/ES521202A0/es active Granted
- 1983-04-02 ES ES521203A patent/ES8405379A1/es not_active Expired
- 1983-04-02 ES ES521201A patent/ES8405377A1/es not_active Expired
- 1983-04-02 ES ES521204A patent/ES521204A0/es active Granted
- 1983-09-07 PH PH29503A patent/PH25053A/en unknown
- 1983-09-07 PH PH29502A patent/PH22654A/en unknown
- 1983-10-03 YU YU01982/83A patent/YU198283A/xx unknown
- 1983-10-03 YU YU1983/83A patent/YU43551B/xx unknown
- 1983-10-03 YU YU01981/83A patent/YU198183A/xx unknown
- 1983-10-31 US US06/546,850 patent/US4587342A/en not_active Expired - Lifetime
- 1983-12-30 US US06/567,248 patent/US4603136A/en not_active Expired - Lifetime
-
1986
- 1986-02-02 RU SU863552053A patent/RU1819264C/ru active
- 1986-03-12 US US06/839,463 patent/US4761475A/en not_active Expired - Lifetime
- 1986-07-17 SG SG626/86A patent/SG62686G/en unknown
- 1986-12-30 MY MY678/86A patent/MY8600678A/xx unknown
-
1987
- 1987-01-14 SU SU874028793A patent/SU1535379A3/ru active
-
1988
- 1988-03-30 HK HK233/88A patent/HK23388A/en not_active IP Right Cessation
- 1988-06-17 AR AR88311165A patent/AR245447A1/es active
- 1988-07-26 YU YU144288A patent/YU46697B/sh unknown
-
1994
- 1994-12-29 NO NO1994029C patent/NO1994029I1/no unknown
Non-Patent Citations (1)
| Title |
|---|
| Патент GB 1133766, кл. С 2 С,опублик. 1968. Патент GB № 1261455, кл. С 2 С, опублик. 1972. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2141322C1 (ru) * | 1997-08-12 | 1999-11-20 | Голощапов Николай Михайлович | Иммуномодулятор с антимикобактериальной активностью "изофон", способ его получения и применения |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1424732A3 (ru) | Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей | |
| FI63244C (fi) | Foerfarande foer framstaellning av antibakteriska erytromysinderivater | |
| CA1213595A (fr) | Acides ¬oxo-4-4h-(|-benzopyran-8-yl| alcanoique sels et derives, preparation | |
| DE69021444T2 (de) | Pteridin-4 (3H)-onen, Verfahren zu ihrer Herstellung und sie enthaltende Medikamente. | |
| US6506911B2 (en) | Pyrano [3,2-d]-1,3-dioxin-8 ones | |
| CZ293482B6 (cs) | DihydropyrimidinyŹ způsob jejich výrobyŹ léčiva tyto látky obsahující a jejich použití | |
| EP0013960B1 (de) | Substituierte Acetophenone, diese enthaltende Präparate und Verfahren zu deren Herstellung | |
| JPS62230767A (ja) | アセトアミド誘導体、その製造方法およびその医薬への応用 | |
| FI58774C (fi) | Saosom insekticider anvaendbara 4-hydroxikinolin- och 4-hydroxitetrahydrokinolinkarbamater | |
| US4714764A (en) | 2-(4-pyridylaminomethyl)-benzimidazole derivatives having antiviral activity | |
| EP0021000B1 (de) | Substituierte Acetophenone, deren Herstellung und pharmazeutische Präparate, die sie enthalten | |
| RU2208610C2 (ru) | Пиперазиновые производные, способ их получения и содержащая их композиция | |
| FR2522000A1 (fr) | Nouvelles thiopyrannopyrimidines, utiles notamment comme agents hypoglycemiants, et leur fabrication | |
| US3325515A (en) | Coumarin derivatives and their preparation | |
| EP0211157B1 (de) | Isoxazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Präparate | |
| JPS6183163A (ja) | 抗腫瘍剤 | |
| SU1039445A3 (ru) | Способ получени производных циклофосфатиазенового р да | |
| US5270465A (en) | 4(3H)-pteridinone compounds | |
| Walker | Michael Addition Products from 2, 3-Dimethoxyphenylpropiolic Acid Derivatives | |
| CN108409654B (zh) | 具有抗肿瘤活性的四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其制药用途 | |
| WO2002024676A1 (en) | N-disubstituted carbamoyloxy flavones | |
| US4334066A (en) | Heterocyclic containing 5-oxo pyrans | |
| SU711035A1 (ru) | Способ получени 2-аминопроизводных 5-этилфеназинона-3 | |
| US3213109A (en) | Aminoalkanol esters of sulfolanylalkanoic acids | |
| US3734931A (en) | 5'-substituted griseofulvins |